These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 28726491)

  • 1. Interview with Thomas Powles: The use of durvalumab in urothelial cancer - the latest strides in immuno-oncology.
    Powles T
    Future Oncol; 2017 Aug; 13(18):1581-1583. PubMed ID: 28726491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durvalumab in non-small-cell lung cancer patients: current developments.
    Mezquita L; Planchard D
    Future Oncol; 2018 Feb; 14(3):205-222. PubMed ID: 29140105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy Combinations and Sequences in Urothelial Cancer: Facts and Hopes.
    Rodriguez-Vida A; Perez-Gracia JL; Bellmunt J
    Clin Cancer Res; 2018 Dec; 24(24):6115-6124. PubMed ID: 29991503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy for metastatic urothelial carcinoma: status quo and the future.
    Necchi A; Rink M; Giannatempo P; Raggi D; Xylinas E
    Curr Opin Urol; 2018 Jan; 28(1):1-7. PubMed ID: 29028766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers for immunotherapy in urological cancers.
    Gust KM; Resch I; D'Andrea D
    Curr Opin Urol; 2018 Jan; 28(1):25-28. PubMed ID: 29120910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Targeted Therapies in Management of Metastatic Urothelial Cancer in the Era of Immunotherapy.
    Grivas P; Yu EY
    Curr Treat Options Oncol; 2019 Jun; 20(8):67. PubMed ID: 31254108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive Biomarkers for Checkpoint Blockade in Urothelial Cancer: A Systematic Review.
    Lavoie JM; Black PC; Eigl BJ
    J Urol; 2019 Jul; 202(1):49-56. PubMed ID: 30730407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer.
    Powles T; Carroll D; Chowdhury S; Gravis G; Joly F; Carles J; Fléchon A; Maroto P; Petrylak D; Rolland F; Cook N; Balar AV; Sridhar SS; Galsky MD; Grivas P; Ravaud A; Jones R; Cosaert J; Hodgson D; Kozarewa I; Mather R; McEwen R; Mercier F; Landers D
    Nat Med; 2021 May; 27(5):793-801. PubMed ID: 33941921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Checkpoint Inhibition in Metastatic Urothelial Cancer.
    Powles T; Smith K; Stenzl A; Bedke J
    Eur Urol; 2017 Oct; 72(4):477-481. PubMed ID: 28413128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Renaissance of immuno-oncology for urological tumors : Current status].
    Grimm MO; Winkler Y; Fetter I; Oppel-Heuchel H
    Urologe A; 2016 May; 55(5):621-6. PubMed ID: 27119960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive biomarkers for immunotherapy in the treatment of advanced urothelial carcinoma: where we stand and where we go.
    Gevaert T; Cimadamore A; Eckstein M; Scarpelli M; Lopez-Beltran A; Cheng L; Montironi R
    Future Oncol; 2019 Jul; 15(19):2199-2202. PubMed ID: 31213082
    [No Abstract]   [Full Text] [Related]  

  • 12. Pembrolizumab in the treatment of advanced urothelial cancer.
    Lundgren KT; Farina MS; Bellmunt J
    Future Oncol; 2017 Dec; 13(30):2745-2758. PubMed ID: 29219016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics.
    Mooradian MJ; Sullivan RJ
    Future Oncol; 2017 Aug; 13(18):1649-1663. PubMed ID: 28776423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy for metastatic urothelial carcinoma: putting the brakes on releasing the brake.
    Zibelman M; Plimack ER
    Immunotherapy; 2018 Mar; 10(6):423-425. PubMed ID: 29562856
    [No Abstract]   [Full Text] [Related]  

  • 15. Cancer Immunotherapy: The Dawn of Antibody Cocktails.
    Marrocco I; Romaniello D; Yarden Y
    Methods Mol Biol; 2019; 1904():11-51. PubMed ID: 30539465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of combination immunotherapies as front-line therapy for non-small-cell lung cancer.
    Santana-Davila R; Chow LQ
    Future Oncol; 2018 Feb; 14(3):191-194. PubMed ID: 29334785
    [No Abstract]   [Full Text] [Related]  

  • 17. The importance for immunoregulation for long-term cancer control.
    Fusi A; Dalgleish A
    Future Oncol; 2017 Aug; 13(18):1619-1632. PubMed ID: 28776411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olaparib recommendations for ovarian cancer patients.
    Johnson P; Westcott G
    Future Oncol; 2016 Jan; 12(2):149-51. PubMed ID: 26616222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy.
    Yan Y; Kumar AB; Finnes H; Markovic SN; Park S; Dronca RS; Dong H
    Front Immunol; 2018; 9():1739. PubMed ID: 30100909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response.
    Sundahl N; De Wolf K; Rottey S; Decaestecker K; De Maeseneer D; Meireson A; Goetghebeur E; Fonteyne V; Verbeke S; De Visschere P; Reynders D; Van Gele M; Brochez L; Ost P
    J Transl Med; 2017 Jun; 15(1):150. PubMed ID: 28662677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.